An anonymous Slashdot reader shared this report from NBC News: A new approach to a routine blood test could predict a person's 30-year risk of heart disease, research published Saturday in the New England Journal of Medicine found.

Doctors have long assessed their patients' risk for cardiovascular disease by using a blood test to look at cholesterol levels, focusing particularly on LDL or "bad" cholesterol. But limiting blood testing to just cholesterol misses important — and usually silent — risk factors, experts say... Lead study author Dr. Paul Ridker, director of the Center for Cardiovascular Disease Prevention at Brigham and Women's Hospital in Boston and his team found that in addition to LDL cholesterol, two other markers — a type of fat in the blood called lipoprotein (a), or Lp(a), and an indicator of inflammation — are important predictors of a person's risk of heart attack, stroke and coronary heart disease...

In the study, the researchers analyzed data from nearly 30,000 U.S. women who were part of the Women's Health Study. On average, the women were 55 years old when they enrolled in the years 1992 through 1995. About 13% — roughly 3,600 participants — had either a heart attack or stroke, had surgery to fix a narrowed or blocked artery, or died from heart disease over the 30-year follow-up period... All of the women had blood tests done at the beginning of the study to measure their LDL cholesterol, Lp(a) and C-reactive protein levels, a marker of inflammation in the body. These measurements, individually as well as together, appeared to predict a woman's heart health over the next three decades, the study found.

Women with the highest levels of LDL cholesterol had a 36% higher risk for heart disease compared with those with the lowest levels. The highest levels of Lp(a) indicated a 33% elevated risk, and those with the highest levels of CRP were 70% more at risk for heart disease. When the three were looked at together, women who had the highest levels were 1.5 times more likely to have a stroke and over three times more likely to develop coronary heart disease over the next 30 years compared with women with the lowest levels.

All of the markers have been individually linked to higher risk of heart disease, but "all three represent different biological processes. They tell us why someone is actually at risk," Ridker said.

"The Big Bang may not have been the beginning of the universe," writes LiveScience, citing "a theory of cosmology that suggests the universe can 'bounce' between phases of contraction and expansion."

The recent study suggests that dark matter could be composed of black holes formed before the Big Bang, during a transition from the universe's last contraction to the current expansion phase... In the new study, researchers explored a scenario where dark matter consists of primordial black holes formed from density fluctuations that occurred during the universe's last contraction phase, not long before the period of expansion that we observe now. They published their findings in June in the Journal of Cosmology and Astroparticle Physics ... In this "bouncing" cosmology, the universe contracted to a size about 50 orders of magnitude smaller than it is today. After the rebound, photons and other particles were born, marking the Big Bang. Near the rebound, the matter density was so high that small black holes formed from quantum fluctuations in the matter's density, making them viable candidates for dark matter.

"Small primordial black holes can be produced during the very early stages of the universe, and if they are not too small, their decay due to Hawking radiation [a hypothetical phenomenon of black holes emitting particles due to quantum effects] will not be efficient enough to get rid of them, so they would still be around now," Patrick Peter, director of research at the French National Centre for Scientific Research (CNRS), who was not involved in the study, told Live Science in an email. "Weighing more or less the mass of an asteroid, they could contribute to dark matter, or even solve this issue altogether."

The scientists' calculations show that this universe mode's properties, such as the curvature of space and the microwave background, match current observations, supporting their hypothesis.
"If this hypothesis holds, the gravitational waves generated during the black hole formation process might be detectable by future gravitational wave observatories, providing a way to confirm this dark matter generation scenario..."

The online news site San Francisco Standard profiles an open-source platform "that takes advantage of large language models to help users generate health insurance appeals with AI...

"A Fight Health Insurance user can scan their insurance denial, and the system will craft several appeal letters to choose from and modify." With the slogan "Make your health insurance company cry too," [San Francisco tech worker Holden Karau's site] makes filing appeals faster and easier. A recent study found that Affordable Care Act patients appeal only about 0.1% of rejected claims, and she hopes her platform will encourage more people to fight back...

The "dirty secret" of the insurance industry is that most denials can be successfully appealed, according to Dr. Harley Schultz, a patient advocate in the Bay Area. "Very few people know about the process, and even fewer take advantage of it, because it's rather cumbersome, arcane, and confusing, by design," he said. "But if you fight hard enough and long enough, most denials get overturned...."

While some doctors have turned to artificial intelligence themselves to fight claims, Karau's service puts the power in the hands of patients, who likely have more time and motivation to dedicate to their claims. "In an ideal world, we would have a different system, but we don't live in an ideal world, so what I'm shooting for here is incremental progress and making the world suck a little less," she said.
Karau estimates she's spent about $10,000 building the platform, according to the article, which adds that "it's free for users, though she might eventually charge for added services like faxing appeals."

Thanks to Slashdot reader mirro_dude for sharing the news.

Though the ocean covers about 70% of earth, we humans have only mapped a quarter of its floor to a high resolution, reports CNN. Many of the world's highest mountains aren't visible on land — they rise up thousands of meters from the seafloor. An expedition to the Nazca Ridge, 900 miles off the coast of Chile, has mapped and explored a newly discovered seamount four times taller than the world's tallest building. What's more, the underwater mountain's peaks, crags and ridges are home to coral gardens that host rare deep-dwelling octopuses, squids and creatures known as flying spaghetti monsters, some of which hadn't been well documented before this research.
The undersea mountain is 1.9 miles (3,109 meters) tall, according to another article, which notes that the researchers also used a sonar system to bounce waves to the ocean floor, timing how long they took to reach the surface: The researchers documented a ghostly white Casper octopus, marking the first time this deep-dwelling cephalopod has been seen in the southern Pacific. They also spotted two rare Bathyphysa siphonophores, sometimes known as flying spaghetti monsters for their stringlike appearance. "The (Casper) octopus has never been captured, so it doesn't actually have a scientific name yet," Virmani said. The team also recorded the first footage of a live Promachoteuthis squid, known only from a few collected specimens.

The Wall Street Journal reports that long Covid "has pushed around one million Americans out of the labor force, economists estimate." More than 5% of adults in the U.S. have long Covid, and it is most prevalent among Americans in their prime working years. About 3.6 million people reported significantly modifying their activities because of the illness in a recent survey by the Centers for Disease Control and Prevention.

Long Covid is a chronic condition with symptoms lasting at least three months after a Covid infection, according to the CDC. Symptoms include fatigue, changes in memory, shortness of breath and trouble concentrating. Long Covid can make tasks as simple as responding to an email arduous, people with the condition say. They struggle to summon the right word or manage stress. Among its many symptoms is post-exertional malaise, which can worsen after even minor physical or mental activity. "People can't go back to work or have to significantly cut down on the amount of work that they can handle," said Akiko Iwasaki, an immunobiology professor at Yale School of Medicine.

Researchers don't know how long symptoms can last. Few people with long Covid have fully recovered within two years. Patients say their doctors have tried everything from antihistamines to blood thinners to physical therapy to acupuncture. Some people might live with the condition for the rest of their lives, said Dr. Paul Volberding, a professor emeritus at the University of California, San Francisco...

Some people with long Covid, which the federal government has classified as a disability, have stayed in their jobs. Human-resource managers have made accommodations including remote work, flexible hours or modified responsibilities, said Rue Dooley of the Society for Human Resource Management. "It's not going away," he said. "It's going to be one of another 100 conditions that we have to grapple with."

People were more likely to develop long Covid at the start of the pandemic, according to a study published in July in the New England Journal of Medicine. The proliferation of vaccines and changes to the virus have made people infected with Covid less likely to develop long Covid.

Scientists have finally detected and measured the ambipolar field, a weak electric field surrounding Earth that was first theorized over 60 years ago. "Any planet with an atmosphere should have an ambipolar field," says astronomer Glyn Collinson of NASA's Goddard Space Flight Center. "Now that we've finally measured it, we can begin learning how it's shaped our planet as well as others over time." ScienceAlert reports: Here's how the ambipolar field was expected to work. Starting at an altitude of around 250 kilometers (155 miles), in a layer of the atmosphere called the ionosphere, extreme ultraviolet and solar radiation ionizes atmospheric atoms, breaking off negatively charged electrons and turning the atom into a positively charged ion. The lighter electrons will try to fly off into space, while the heavier ions will try to sink towards the ground. But the plasma environment will try to maintain charge neutrality, which results in the emergence of an electric field between the electrons and the ions to tether them together. This is called the ambipolar field because it works in both directions, with the ions supplying a downward pull and the electrons an upward one. The result is that the atmosphere is puffed up; the increased altitude allows some ions to escape into space, which is what we see in the polar wind.

This ambipolar field would be incredibly weak, which is why Collinson and his team designed instrumentation to detect it. The Endurance mission, carrying this experiment, was launched in May 2022, reaching an altitude of 768.03 kilometers (477.23 miles) before falling back to Earth with its precious, hard-won data. And it succeeded. It measured a change in electric potential of just 0.55 volts -- but that was all that was needed. "A half a volt is almost nothing -- it's only about as strong as a watch battery," Collinson says. "But that's just the right amount to explain the polar wind." That amount of charge is enough to tug on hydrogen ions with 10.6 times the strength of gravity, launching them into space at the supersonic speeds measured over Earth's poles. Oxygen ions, which are heavier than hydrogen ions, are also lofted higher, increasing the density of the ionosphere at high altitudes by 271 percent, compared to what its density would be without the ambipolar field. The findings have been published in the journal Nature.

For decades drugmakers have taken a more-is-more model when dosing cancer drugs in clinical trials. U.S. regulators want them to reconsider that approach. From a report: Companies with cancer drugs in clinical trials must strike a balance between doses high enough to thwart tumors, but low enough to avoid intolerable side effects. For years, Food and Drug Administration officials have expressed concern that cancer drug doses are often too high, leading to unnecessary side effects.

An FDA program launched in 2021, Project Optimus, requires companies to re-examine how they set doses of cancer treatments. This typically involves larger clinical trials to test doses to find those that optimally balance safety and efficacy. Entrepreneurs support the aim, but some fear the initiative will add time and cost to drug development, putting startups at a further disadvantage to larger competitors. [...] The FDA says it encourages drugmakers to discuss dosing plans with the agency and that new medications can still be brought to patients quickly.

A new AI model being developed by Google could make diagnosing tuberculosis and other respiratory ailments as easy as recording a voice note. From a report: Google is training one of its foundational AI models to listen for signs of disease using sound signals, like coughing, sneezing, and sniffling. This tech, which would work using people's smartphone microphones, could revolutionize diagnoses for communities where advanced diagnostic tools are difficult to come by.

The tech giant is collaborating with Indian respiratory health care AI startup, Salcit Technologies. The tech, which was introduced earlier this year as Health Acoustic Representations, or HeAR, is what's known as a bioacoustic foundation model. HeAR was then trained on 300 million pieces of audio data, including 100 million cough sounds, to learn to pick out patterns in the sounds. Salcit is then using this AI model, in combination with its own product Swaasa, which uses AI to analyze cough sounds and assess lung health, to help research and improve early detection of TB based solely on cough sounds.

Astronomy researchers are urging the FCC to reconsider exempting large constellations of low Earth satellites from environmental reviews due to growing concerns over pollution, safety risks, and the impact on stargazing. They argue that the decades-old exemption is outdated, given the massive increase in satellite launches and potential long-term effects on the ozone, climate, and environment. The Register reports: Astronomers from Princeton University, University of California, Berkeley, and University of Arizona, among others, have added their names to a public letter that will be presented at some point to FCC space bureau chief Julie Kearney. The letter asks the FCC to follow prior recommendations from the Government Accountability Office (GAO), which in 2022 issued a report calling for the telecom regulator to revisit its decision to exempt large constellations of satellites from environmental review.

The exemption was created way back in 1986, when far fewer satellites were being launched. The GAO, however, urged the FCC to review the exemption, citing the recent proliferation of satellites and the questions that have been raised about the sustainability of the exemption. That recommendation was recently echoed by US PIRG, which earlier this month made a similar request to the FCC. US PIRG notes that the number of satellites in low Earth orbit has increased by a factor of 127 over the past five years, driven largely by the deployment of mega-constellations of communications satellites from SpaceX's Starlink subsidiary.

Scientists are harvesting genetic data from microorganisms in a North Yorkshire quarry, fueling a global debate over ownership and profit-sharing of natural genetic resources. Researchers from London-based startup Basecamp Research are collecting samples and digitizing genetic codes for sale to AI companies. This practice of trading digital sequencing information (DSI) has become central to biotechnology research and development. The issue will be a focal point at October's COP16 biodiversity summit in Cali, Colombia, The Guardian reports.

Developing nations, home to much of the world's biodiversity, are pushing for a global system requiring companies to pay for genetic data use. Past discoveries underscore the potential value: heat-resistant bacteria crucial for COVID-19 testing and marine organisms used in cancer treatments have generated significant profits. Critics accuse companies of "biopiracy" for commercializing genetic information without compensating source countries. Proposed solutions include a global fund for equitable benefit-sharing, though implementation details remain contentious.

An anonymous reader quotes a report from Scientific American, written by science journalist Simon Makin: The persistence of memory is crucial to our sense of identity, and without it, there would be no learning, for us or any other animal. It's little wonder, then, that some researchers have called how the brain stores memories the most fundamental question in neuroscience. A milestone in the effort to answer this question came in the early 1970s, with the discovery of a phenomenon called long-term potentiation, or LTP. Scientists found that electrically stimulating a synapse that connects two neurons causes a long-lasting increase in how well that connection transmits signals. Scientists say simply that the "synaptic strength" has increased. This is widely believed to be the process underlying memory. Networks of neural connections of varying strengths are thought to be what memories are made of.

In the search for molecules that enable LTP, two main contenders emerged. One, called PKMzeta (protein kinase Mzeta), made a big splash when a 2006 study showed that blocking it erased memories for places in rats. If obstructing a molecule erases memories, researchers reasoned, that event must be essential to the process the brain uses to maintain memories. A flurry of research into the so-called memory molecule followed, and numerous experiments appeared to show that it was necessary and sufficient for maintaining numerous types of memory. The theory had a couple of holes, though. First, PKMzeta is short-lived. "Those proteins only last in synapses for a couple of hours, and in neurons, probably a couple of days," says Todd Sacktor, a neurologist at SUNY Downstate Health Sciences University, who was co-senior author of the 2006 study. "Yet our memories can last 90 years, so how do you explain this difference?" Second, PKMzeta is created in cells as needed, but then it has to find the right synapses. Each neuron has around 10,000 synapses, only a few percent of which are strengthened, says neuroscientist Andre Fenton, the other co-senior author of the 2006 study, who is now at New York University. The strengthening of some synapses and not others is how this mechanism stores information, but how PKMzeta molecules accomplish this was unknown.

A new study published in Science Advances by Sacktor, Fenton and their colleagues plugs these holes. The research suggests that PKMzeta works alongside another molecule, called KIBRA (kidney and brain expressed adaptor protein), which attaches to synapses activated during learning, effectively "tagging" them. KIBRA couples with PKMzeta, which then keeps the tagged synapses strengthened. Experiments show that blocking the interaction between these two molecules abolishes LTP in neurons and disrupts spatial memories in mice. Both molecules are short-lived, but their interaction persists. "It's not PKMzeta that's required for maintaining a memory, it's the continual interaction between PKMzeta and this targeting molecule, called KIBRA," Sacktor says. "If you block KIBRA from PKMzeta, you'll erase a memory that's a month old." The specific molecules will have been replaced many times during that month, he adds. But, once established, the interaction maintains memories over the long term as individual molecules are continually replenished. [...] "What seems clear is that there is no single 'memory molecule,'" concludes Scientific American. "Regardless of any competing candidate, PKMzeta needs a second molecule to maintain long-term memories, and there is another that can substitute in a pinch."

"There are also some types of memory, such as the association of a location with fear, that do not depend on PKMzeta," the report adds. "Nobody knows what molecules are involved in those cases, and PKMzeta is clearly not the whole story."

SpaceX's Falcon 9 rocket has been grounded by the FAA for the second time in less than two months following the failed landing of a first-stage booster, which was destroyed in a fireball after its 23rd flight. Spaceflight Now reports: The booster, serial number B1062 in the SpaceX fleet, suffered a hard landing, at the tail end of its record-setting 23rd flight. It was consumed in a fireball on the deck of the drone ship 'A Shortfall of Gravitas', which was stationed in the Atlantic Ocean about 250 miles east of Charleston, South Carolina. The mishap was the first booster landing failure since February 2021. In a statement on Wednesday, the Federal Aviation Administration said that while no public injuries or public property damage was reported, "The FAA is requiring an investigation."

The FAA made a similar declaration following a Falcon 9 upper-stage failure on July 12 during the Starlink 9-3 mission, which resulted in the loss of 20 satellites. Following that incident, SpaceX rockets did not return to flight until the Starlink 10-9 mission, on July 27. [...] The booster failure came the same week that SpaceX had to twice delay a launch attempt of the Polaris Dawn astronaut mission, first due to a helium leak and then for recovery weather at the end of the mission. The Polaris Dawn crew remain in quarantine for now, according to social media posts from Isaacman, but the timing of the next launch attempt is uncertain. In addition to landing weather concerns and resolving the FAA investigation, there is also the matter of launch pad availability.

Data from giant project show how withdrawn research propagates through the literature. Nature: In January, a review paper about ways to detect human illnesses by examining the eye appeared in a conference proceedings published by the Institute of Electrical and Electronics Engineers (IEEE) in New York City. But neither its authors nor its editors noticed that 60% of the papers it cited had already been retracted. The case is one of the most extreme spotted by a giant project to find papers whose results might be in question because they cite retracted or problematic research. The project's creator, computer scientist Guillaume Cabanac at the University of Toulouse in France, shared his data with Nature's news team, which analysed it to find the papers that most heavily cite retracted work yet haven't themselves been withdrawn.

"We are not accusing anybody of doing something wrong. We are just observing that in some bibliographies, the references have been retracted or withdrawn, meaning that the paper may be unreliable," Cabanac says. He calls his tool a Feet of Clay Detector, referring to an analogy, originally from the Bible, about statues or edifices that collapse because of their weak clay foundations. The IEEE paper is the second-highest on the list assembled by Nature, with 18 of the 30 studies it cites withdrawn. Its authors didn't respond to requests for comment, but IEEE integrity director Luigi Longobardi says that the publisher didn't know about the issue until Nature asked, and that it is investigating. Cabanac, a research-integrity sleuth, has already created software to flag thousands of problematic papers in the literature for issues such as computer-written text or disguised plagiarism. He hopes that his latest detector, which he has been developing over the past two years and describes this week in a Comment article in Nature, will provide another way to stop bad research propagating through the scientific literature -- some of it fake work created by 'papermill' firms.

ole_timer shares a report from Ars Technica, written by Beth Mole There's more bad news for the company behind an experimental MDMA therapy for post-traumatic stress disorder, which the Food and Drug Administration roundly rejected earlier this month. According to a report from The Wall Street Journal, the FDA is now expanding an investigation into clinical trials behind the experimental psychedelic therapy -- even though the agency has already rejected it. Agency investigators reportedly interviewed four additional people last week, asking questions regarding whether the trials underreported side effects.

People involved in the trial have previously alleged, among other things, that ill effects, such as suicidal thoughts, went undocumented, and trial participants were discouraged from reporting them to bolster the chances of FDA approval. Overall, the MDMA trials faced crushing criticism amid the FDA's review, with outside experts and agency advisers calling out allegations of sexual misconduct at one trial site, as well as flaws in overall trial designs, multiple sources of biases, and claims that the company behind the therapy, Lykos, fostered a cult-like belief in psychedelics.

According to the Journal, the recent interviews were being conducted by the FDA's Office of Regulatory Affairs, which oversees inspections, and a subdivision of that office called Biomedical Research Monitoring Program, which works to ensure the quality and integrity of data submitted to FDA. Notably, when the agency rejected MDMA, it advised Lykos to conduct a new trial. While the FDA's rejection and expanded investigation are bad enough for Lykos, the company announced this month that it's laying off 75 percent of its staff and overhauling its leadership. The moves were in response to the FDA's rejections, the company said. Additionally, a scientific journal retracted three of the company's MDMA studies, citing "protocol violations amounting to unethical conduct" in its trials, echoing claims raised amid the FDA review.

A type of genetically modified wheat developed by Argentina's Bioceres may be safely grown and bred in the United States, the U.S. Department of Agriculture said on Tuesday. From a report: Bioceres must still complete additional steps, including field trials, that will take years before it can commercialize HB4 wheat, modified to tolerate drought, industry group U.S. Wheat Associates said. Still, USDA's finding moves genetically modified wheat closer to production in the U.S. in a potential win for farmers grappling with drought and more severe weather, despite concerns among some consumers.

"Wherever wheat is grown in the world, drought takes its toll on yields and quality, so an innovation like HB4 holds a lot of interest for growers like me," said Michael Peters, an Oklahoma wheat farmer and past chairman of U.S. Wheat Associates. Genetic modification involves altering a plant's makeup by transferring DNA from one organism to another and is common in crops such as corn, used for livestock feed. Some consumer groups oppose genetic modification of wheat over concerns about human health since it is widely used to make bread and pasta, and therefore consumed directly by people. USDA's decision on HB4 wheat is farther than the agency has ever gone with genetically modified wheat, U.S. Wheat Associates said.